首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >New mixed ligand zinc(II) complexes based on the antiepileptic drug sodium valproate and bioactive nitrogen-donor ligands. Synthesis, structure and biological properties
【24h】

New mixed ligand zinc(II) complexes based on the antiepileptic drug sodium valproate and bioactive nitrogen-donor ligands. Synthesis, structure and biological properties

机译:基于抗癫痫药丙戊酸钠和生物活性氮供体配体的新型混合配体锌(II)配合物。合成,结构和生物学特性

获取原文
获取原文并翻译 | 示例
           

摘要

Starting from the precursor [Zinc Valproate complex] (1), new mixed ligand zinc(II) complexes of valproic acid and nitrogen-based ligands, formulating as, [Zn(valp)(2)2,9-dmphen] (2), [Zn-2(valp)(4)(quin)(2)] (3), [Zn(valp)(2)(2-ampy)(2)] (4), and [Zn(valp)(2)(2-ampic)(2)] (5) (valp = valproate, 2,9-dmphen = 2,9-dimethyl-1,10-phenanthroline, quin = quinoline, 2-ampy = 2-aminopyridine, 2-ampic = 2-amino-6-picoline) were synthesized and characterized using IR, H-1 NMR, C-13{H-1} NMR and UV-Vis spectrometry. The crystal structures of complexes 2, 3 and 4 were determined using single-crystal X-ray diffraction. The complexes were also evaluated for their anti-bacterial activity using in-vitro agar diffusion method against three Gram-positive (Micrococcus luteus, Staphylococcus aureus, and Bacillus subtilis) and three Gram-negative (Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis) species. Complex 2 showed considerable activity against all tested microorganisms and the effect of complexation on the anti-bacterial activity of the parent ligand of 2 was also investigated. The anti-bacterial activity of 2,9-dmphen against Gram-negative bacteria was enhanced upon complexation with zinc valproate. On the other hand, complexes 1 and 3 showed weak inhibition activity against the tested species and complexes 4 and 5 didn't show any activity at all. Two methods were used for testing the inhibition of ferriprotoporphyrinIX biomineralization: a semi-quantitative micro-assay and a previously self-developed quantitative in-vitro method. Both were used to study the efficiency of these complexes in inhibiting the formation of the Malaria pigment which considered being the target of many known anti-malarial drugs such as Chloroquine and Amodiaquine. Results showed that the efficiency of complex 2 in preventing the formation of beta-Hematin was 80%. The efficiency of Amodiaquine as a standard drug was reported to give 91%. (C) 2014 Elsevier Masson SAS. All rights reserved.
机译:从前体[丙戊酸锌配合物](1)开始,制备丙戊酸和氮基配体的新型混合配体锌(II)配合物,公式为[Zn(valp)(2)2,9-dmphen](2) ,[Zn-2(valp)(4)(quin)(2)](3),[Zn(valp)(2)(2-ampy)(2)](4)和[Zn(valp)( 2)(2-ampic)(2)](5)(valp =丙戊酸,2,9-dmphen = 2,9-二甲基-1,10-菲咯啉,quin =喹啉,2-ampy = 2-氨基吡啶,2 (-ampic = 2-amino-6-picoline)合成并使用IR,H-1 NMR,C-13 {H-1} NMR和UV-Vis光谱进行表征。配合物2、3和4的晶体结构使用单晶X射线衍射确定。还使用体外琼脂扩散方法评估了复合物对三种革兰氏阳性菌(微球菌,金黄色葡萄球菌和枯草芽孢杆菌)和三种革兰氏阴性菌(大肠杆菌,肺炎克雷伯菌和肺炎变形杆菌)的抗菌活性。种类。复合物2显示出对所有测试微生物的相当大的活​​性,并且还研究了复合物对2的母体配体的抗菌活性的影响。与丙戊酸锌络合后,2,9-dmphen对革兰氏阴性细菌的抗菌活性增强。另一方面,复合物1和3对被测物种的抑制活性较弱,复合物4和5根本没有任何活性。两种方法用于测试对铁原卟啉IX生物矿化的抑制作用:半定量微量测定法和先前自行开发的定量体外方法。两者均用于研究这些复合物抑制疟疾色素形成的效率,而疟疾色素被认为是许多已知的抗疟疾药物如氯喹和阿莫二喹的靶标。结果表明,复合物2阻止β-血红素形成的效率为80%。据报道,阿莫地喹作为标准药物的效率为91%。 (C)2014 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号